NeuroPace (NPCE) Revenue Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.51 Bn | 174.21 Bn | 6.27 Bn | 7.78% |
| 2 | Stryker | 128.52 Bn | 125.64 Bn | 3.81 Bn | 2.63% |
| 3 | Medtronic | 108.06 Bn | 98.84 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 68.04 Bn | 66.59 Bn | 3.61 Bn | 11.58% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | 16.70% |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 7.41% |
| 7 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn | 15.05% |
| 8 | Smith & Nephew | 26.88 Bn | 26.30 Bn | - | - |
| 9 | Koninklijke Philips | 25.42 Bn | 22.29 Bn | 2.07 Bn | 6.08% |
| 10 | NeuroPace | 517.38 Mn | 463.40 Mn | 18.05 Mn | -2.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.02% |
| Dec 31, 2025 | 23.86% |
| Sep 30, 2025 | 29.89% |
| Jun 30, 2025 | 22.14% |
| Mar 31, 2025 | 24.28% |
| Dec 31, 2024 | 19.18% |
| Sep 30, 2024 | 28.20% |
| Jun 30, 2024 | 16.63% |
| Mar 31, 2024 | 25.23% |
| Dec 31, 2023 | 40.84% |
| Sep 30, 2023 | 47.23% |
| Jun 30, 2023 | 61.86% |
| Mar 31, 2023 | 27.24% |
| Dec 31, 2022 | 16.30% |
| Sep 30, 2022 | 7.91% |
| Jun 30, 2022 | -19.24% |
| Mar 31, 2022 | 1.40% |
| Dec 31, 2021 | 2.28% |
| Sep 30, 2021 | -19.04% |
| Jun 30, 2021 | 65.31% |